Analyst Ratings For Alimera Sciences Inc (NASDAQ:ALIM)
Today, HC Wainwright reiterated its Buy rating on Alimera Sciences Inc (NASDAQ:ALIM) with a price target of $2.75.
There are 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Alimera Sciences Inc (NASDAQ:ALIM) is Buy with a consensus target price of $2.8333 per share, a potential 144.25% upside.
Some recent analyst ratings include
- 3/7/2019-Alimera Sciences Inc (NASDAQ:ALIM) had its Buy rating reiterated by HC Wainwright with a $2.75 price target
- 9/5/2018-Alimera Sciences Inc (NASDAQ:ALIM) had its Buy rating reiterated by Cowen with a $3.00 price target
- 6/29/2018-Alimera Sciences Inc (NASDAQ:ALIM) has coverage initiated with a Buy rating and $2.75 price target
- 4/27/2017-Alimera Sciences Inc (NASDAQ:ALIM) has coverage initiated with a Buy ➝ Buy rating and $4.00 price target
- On 5/7/2018 Richard S Eiswirth Jr, Insider, bought 10,000 with an average share price of $1.05 per share and the total transaction amounting to $10,500.00.
- On 2/6/2018 Armistice Capital Master Fund, Major Shareholder, bought 20,000 with an average share price of $1.14 per share and the total transaction amounting to $22,800.00.
- On 2/2/2018 Armistice Capital, Llc, Major Shareholder, bought 8,000 with an average share price of $1.16 per share and the total transaction amounting to $9,280.00.
- On 1/19/2018 C. Daniel Myers, CEO, sold 52,900 with an average share price of $1.20 per share and the total transaction amounting to $63,480.00.
- On 1/19/2018 Philip Ashman, SVP, sold 25,500 with an average share price of $1.20 per share and the total transaction amounting to $30,600.00.
- On 1/19/2018 Richard S Eiswirth Jr, Insider, sold 13,410 with an average share price of $1.20 per share and the total transaction amounting to $16,092.00.
- On 1/17/2018 C. Daniel Myers, CEO, sold 52,900 with an average share price of $1.23 per share and the total transaction amounting to $65,067.00.
About Alimera Sciences Inc (NASDAQ:ALIM)
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has an agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat DME. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Recent Trading Activity for Alimera Sciences Inc (NASDAQ:ALIM)
Shares of Alimera Sciences Inc closed the previous trading session at 1,16 −0,030 2,52 % with 1.14 shares trading hands.